Spanoudakis, E.; Papoutselis, M.; Bazntiara, I.; Lamprianidou, E.; Kordella, X.; Tilkeridis, C.; Tsatalas, C.; Kotsianidis, I. THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION. Mediterr J Hematol Infect Dis 2018, 10, e2018058.